

Economics of Self-Measured Blood Pressure Monitoring: A Community Guide Systematic Review



Verugheese Jacob, PhD, MPH,¹ Sajal K. Chattopadhyay, PhD,¹ Krista K. Proia, MPH,² David P. Hopkins, MD, MPH,¹ Jeffrey Reynolds, MPH,¹ Anilkrishna B. Thota, MBBS, MPH,¹ Christopher D. Jones, PhD, MSW,³ Daniel T. Lackland, DrPH,⁴ Kimberly J. Rask, MD, PhD,⁵ Nicolaas P. Pronk, PhD, MA,^{6,7} John M. Clymer, BA,⁸ Ron Z. Goetzel, PhD, MA^{9,10} and the Community Preventive Services Task Force

Context: The health and economic burden of hypertension, a major risk factor for cardiovascular disease, is substantial. This systematic review evaluated the economic evidence of self-measured blood pressure (SMBP) monitoring interventions to control hypertension.

Evidence acquisition: The literature search from database inception to March 2015 identified 22 studies for inclusion with three types of interventions: SMBP used alone, SMBP with additional support, and SMBP within team-based care (TBC). Two formulae were used to convert reductions in systolic BP (SBP) to quality-adjusted life years (QALYs) to produce cost per QALY saved. All analyses were conducted in 2015, with estimates adjusted to 2014 U.S. dollars.

Evidence synthesis: Median costs of intervention were \$60 and \$174 per person for SMBP alone and SMBP with additional support, respectively, and \$732 per person per year for SMBP within TBC. SMBP alone and SMBP with additional support reduced healthcare cost per person per year from outpatient visits and medication (medians \$148 and \$3, respectively; median follow-up, 12–13 months). SMBP within TBC exhibited an increase in healthcare cost (median, \$369 per person per year; median follow-up, 18 months). SMBP alone varied from cost saving to a maximum cost of \$144,000 per QALY saved, with two studies reporting an increase in SBP. The two translated median costs per QALY saved were \$2,800 and \$4,000 for SMBP with additional support and \$7,500 and \$10,800 for SMBP within TBC.

Conclusions: SMBP monitoring interventions with additional support or within TBC are cost effective. Cost effectiveness of SMBP used alone could not be determined.

Am J Prev Med 2017;53(3):e105–e113. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine

CONTEXT

High blood pressure (BP) is an important risk factor for cardiovascular disease (CVD) and stroke in the U.S., accounting annually for more

than \$193 billion in medical care and about \$123 billion in lost productivity in 2011–2012.¹ The control of high BP with medication and other treatments can prevent and avert a substantial part of this societal burden,² even

From the ¹Community Guide Branch, Division of Public Health Information Dissemination, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; ²Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, Georgia; ³Division for Heart Disease and Stroke Prevention, Office of Noncommunicable Diseases, Injury, and Environmental Health, CDC, Atlanta, Georgia; ⁴Medical University of South Carolina, Charleston, South Carolina; ⁵Emory University, Alliant Health Solutions, Atlanta, Georgia; ⁶HealthPartners Institute, Minneapolis, Minnesota; ⁷Harvard T.H. Chan School of Public Health, Boston, Massachusetts; ⁸National Forum for Heart

Disease and Stroke Prevention, Washington, District of Columbia; ⁹Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and ¹⁰Truven Health Analytics, Bethesda, Maryland

Names and affiliations of Task Force members are available at: www.thecommunityguide.org/task-force/community-preventive-services-task-force-members.

Address correspondence to: Verugheese Jacob, PhD, MPH, Community Guide Branch, CDC, 1600 Clifton Road, Mailstop E69, Atlanta GA 30329. E-mail: hir0@cdc.gov.

0749-3797/\$36.00

<https://doi.org/10.1016/j.amepre.2017.03.002>




Figure 1. Economics of SMBP monitoring interventions to improve BP control.

BP, blood pressure; CVD, cardiovascular disease; LY, life years; QALY, quality-adjusted life years; SMBP, self-measured blood pressure; TBC, team-based care.

as costs are projected to increase with hypertension-related outcomes, such as stroke, in a growing and aging population.³ For example, hypertension control efforts have contributed to the decline in stroke mortality because distributions of population systolic BP (SBP) have shifted.⁴

Self-measured blood pressure (SMBP) monitoring interventions use BP monitoring devices operated by patients to improve the management of high BP. This process provides clinicians with accurate and frequent measurements, increases patient engagement in their own care, and prompts patients to adopt healthful lifestyles. A recent systematic review^{5,6} conducted for the Agency for Healthcare Research and Quality showed that SMBP monitoring interventions, typically in the home, were effective in improving BP outcomes in patients with high BP, reducing SBP by 3.2–4.6 mmHg and diastolic BP by 1.3–2.3 mmHg.⁷ However, there has been no published review of the economics of these interventions.

The objective of the present paper is to assess the cost and economic benefit of SMBP monitoring interventions based on a systematic review of the literature.

EVIDENCE ACQUISITION

Concepts and Methods

This study was conducted using Community Guide methods for systematic economic reviews, available at www.thecommunityguide.org/about/economic-reviews. A review team (the team) was constituted, including subject matter experts on CVD and hypertension from various agencies, organizations, and academic institutions together with experts in systematic reviews from the Community Guide Branch at the Centers for Disease Control and Prevention. The team worked under the oversight of the Community Preventive Services Task Force.

Interventions with SMBP monitoring involve use of personal BP measurement devices to improve the treatment of high BP. Patients are trained to use these devices in familiar settings, such as their homes. Readings are shared with their healthcare providers during clinic visits, by telephone, or electronically, and are monitored and used in treatment decisions to improve BP control. These interventions also may involve support such as medication and lifestyle counseling, patient education for self-management, and telephone or web-based tools.

Such SMBP interventions often are delivered within team-based care (TBC) for BP control, in which primary care providers and patients work together with other providers to improve the efficiency of care delivery and self-management support for patients.

A novel feature of the present review is the categorization of SMBP monitoring interventions into interventions implementing SMBP alone, SMBP with additional support, and SMBP within TBC. Distinction is drawn between additional support and team-based care because the latter is far more comprehensive and resource intensive than SMBP interventions that add web- or phone-enabled patient support. Further, SMBP alone and SMBP with additional support are both capital intensive, whereas SMBP within TBC is more labor intensive.

Although the focus of the Agency for Healthcare Research and Quality effectiveness review^{5,6} of SMBP interventions was on treatment and management of high BP, this economic review also recognizes the diagnostic function of home BP monitors because identification of “white coat hypertension” and masked hypertension^{8,9} in a population can have substantial implications for healthcare resource use.¹⁰

Figure 1 depicts the intervention, the population, and transitions in health status ascribed to the intervention (Intervention Effectiveness), below which appear associated resource use and

“Patients with isolated high blood pressure in the medical setting and in the presence of medical personnel are said to have “white coat hypertension.” Patients with controlled blood pressure measured in the clinic and uncontrolled blood pressure when measured outside the clinic are said to have “masked hypertension.”

economic benefits (Economic Outcomes). This economic review takes a societal perspective, which means costs and economic benefits are aggregated regardless of who pays and who benefits. The following research questions are considered based on the economic effects of the intervention illustrated in [Figure 1](#):

- What is the cost to implement the intervention?
- What is the effect of the intervention on healthcare cost?
- What is the effect of the intervention on productivity of patients at their workplaces?
- What is the net economic benefit of the intervention?
- What is the cost effectiveness of the intervention? In particular, what is cost per quality-adjusted life year (QALY) saved?

The target population of the interventions for this review are patients diagnosed with hypertension in primary care. Studies focused on patients with established CVD, gestational hypertension, and those receiving dialysis were excluded as were those focused on patients with illnesses that prevent them from using the home BP devices. Only published studies of interventions implemented in high-income countries were included. No restrictions were placed on study design. Studies included in the economic review had to contain information that would address one or more of the review's research questions. The measurement and estimation of economic effects associated with each of the research questions are described in detail below.

Intervention Cost. SMBP interventions require devices, materials, and labor to implement, which are captured in estimates for intervention cost ([Figure 1](#)). The components of intervention cost for SMBP-alone interventions are the BP monitoring device, patient training on correct use of the device, any telemetry device to transmit the BP readings, and the cost of generating summary reports for the care provider. SMBP with additional support adds the cost of other devices (e.g., smartphones); staff; development of interactive software; and other information technology necessary to support patient self-care in addition to providers' time to review patients' BP reports to aid counseling and treatment. SMBP within TBC adds the cost of administrative and medical staff engaged in TBC activities. Estimates of intervention cost are considered reasonably complete if they include these components that are cost drivers: the BP device in the case of SMBP-alone interventions; the BP device and patient support in the case of SMBP with additional support; and the BP device, patient support, and TBC activities for SMBP within TBC.

Healthcare Cost. [Figure 1](#) shows the changes in healthcare resource use expected from the intervention, leading to change in healthcare cost. The components of healthcare cost are outpatient visits; medications; labs; emergency room (ER) visits; and inpatient stays. The effect of SMBP interventions on healthcare cost likely occurs through several channels. Identification of white coat and masked hypertension can alter the number of patients who need treatment. Changes in medication adherence, lifestyle, and BP control related to the intervention have effects on medication utilization, outpatient visits, and labs in the short term and on inpatient and ER visits in the longer term. The directions these changes take are empirical questions. For example, improved adherence to medication may increase refills and medication cost. On the other hand, improved BP control may prompt the provider to reduce medication. In the case of outpatient visits, the expectation is that home-based BP monitoring will reduce clinic visits

solely for BP checks. Or it could be that home readings that exceed the threshold may alarm patients and increase contact with the clinic. In the long term, however, the expectation is that these interventions improve BP control and hence avert CVD events, resulting in averted inpatient and ER visits. Therefore, this economic review addresses the interventions' net effect on health-care cost, both in the short and long term. Based on completeness of reporting in the included studies, estimates of healthcare cost for SMBP alone and for SMBP with additional support interventions were considered reasonable if they included outpatient visits and medication; those for SMBP within TBC interventions were considered reasonable if they included outpatient visits, medication, and inpatient stays.

Total Cost and Cost Effectiveness. The quantity and quality of years lived increase when CVD morbidity and mortality are averted by effective SMBP interventions. Cost-effectiveness analysis seeks estimates for cost per QALY saved, where cost (total cost) is the sum of intervention cost and change in healthcare cost. An intervention is considered cost effective if the cost per QALY saved is less than a conservative threshold of \$50,000.^{11,12} The present review translated reductions in SBP to QALYs saved¹³ to assess cost effectiveness for studies that reported the change in BP resulting from intervention. Two translations from the published literature were used: Translation (1), for which a reduction of 1 mmHg of SBP=0.009 QALY saved¹⁴; and Translation (2), for which a reduction of 1 mmHg of SBP=0.093 QALY saved.¹⁵ Estimates based on both translations were evaluated, as a sensitivity measure, because the two equations relating change in SBP to QALYs were based on trial populations that differed in age and in the method used to derive QALY weights. The 20-year cost per QALY saved was based on total cost and increase in QALY per person per year summed over 20 years at a 3% discount rate. For the second formula, the increase in QALY was already reflected over life time of patients.

Productivity in the Workplace. Finally, reduced morbidity and mortality related to SMBP interventions translate to higher productivity of patients at their jobs as a consequence of reduced illness and absences, better performance when at work, and increased working years. A complete cost-benefit assessment, as in a cost-benefit ratio, considers changes needed in resources to carry out the intervention, as well as the changes in healthcare cost and worksite productivity.

Economic results and conclusions are presented separately for SMBP alone, SMBP with additional support, and SMBP within TBC. All monetary values are in 2014 U.S. dollars, adjusted for inflation using the Consumer Price Index,¹⁶ and converted from foreign currency denominations using purchasing power parities.¹⁷ All analyses were conducted in 2015.

Search Strategy

The original search strategy from the review of effectiveness,^{5,6} available at www.thecommunityguide.org/findings/cardiovascular-disease-self-measured-blood-pressure-with-additional-support, was extended for the economic review. In addition to the original search in MEDLINE and Cochrane, new sources were EconLit and databases maintained at the Centre for Reviews and Dissemination at the University of York. The search period was extended to March 2015 from February 2013, the end of the original search. Studies of interventions that met the definition,

were conducted in high-income countries,¹⁸ and contained information on economic cost or economic benefit of intervention were included in the review. Reference lists of included studies were also searched, as were action guides from the Million Hearts Initiative^{19,20} and studies recommended for inclusion by subject matter experts.

EVIDENCE SYNTHESIS


Results

A total of 1,246 papers were screened, yielding 22 studies in 29 papers^{21–49} for inclusion (Figure 2). Appendix Table 1 (available online) provides a summary of the study characteristics in terms of design, intervention group size and age, length of intervention, comparison group, setting, and what economic outcomes were actually measured within the study and which were modeled. The substantial majority of the studies were RCTs with usual care as the comparison group, and patient care took place in the primary care setting. The average age of the study patients was about 57 years. Papers that covered the same population and intervention are considered single studies and are identified in Appendix Tables 3–6 (available online). Eight studies from 11 papers^{21–31} provided economic evidence for SMBP alone, eight studies^{32–39} for SMBP with additional support, and eight studies^{22,27,33,40–49} for SMBP within TBC. Although several studies reported intervention cost and effects on healthcare cost, none reported productivity effects. No studies performed a cost–benefit analysis that included productivity effects. Only one³⁵ study modeled the outcomes to cost per QALY saved. Translated cost per QALY saved estimates were derived for the 11 studies^{22–24,27,29–31,33,35,36,38,41,42,44,49} that provided both change in SBP and the total cost of the intervention.

Studies used BP devices as a tool to guide treatment, as a diagnostic tool, or both. Appendix Table 2 (available online) provides additional details on how the home BP devices were used in the interventions and how that may have affected economic outcomes considered in this review. Most studies were of patients with high BP, based on usual clinic measurements. Most of the SMBP-alone studies included the diagnostic impact in addition to treatment impact, based on home BP readings. No studies of SMBP with additional support and only one study of SMBP within TBC reported economic outcomes that included the impact of home BP devices used as a diagnostic tool.

Table 1 provides estimates of intervention cost and change in healthcare cost following the intervention. The median cost to implement the intervention increased from \$60 per person for SMBP alone, to \$174 per person with the addition of patient support, and to \$732 per person per year implemented within TBC. A substantial part of intervention cost for both SMBP alone and SMBP with additional support was the cost of the BP monitor. One study^{46–48} of SMBP within TBC was excluded as an outlier for intervention cost because it reported a very high cost of intervention that included diabetes case management and telemedicine hardware and software developed specifically for the study. The change in all-cause healthcare cost reported for this study was included in median estimates because hypertension is a major risk factor for CVD and subsequent healthcare utilization for those with diabetes. Individual study details along with components of intervention cost included in the estimate are presented in Appendix Table 3 (available online).

Detailed estimates for change in healthcare cost related to intervention are shown in Appendix Table 4 (available online). Most studies on SMBP alone, and SMBP with



*Uhlrig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. *Ann Intern Med.* 2013;159(3):185-194.

Figure 2. Economic evidence search yield.

AHRQ, Agency for Healthcare Research and Quality; SME, subject matter expert.

Table 1. Intervention Cost and Change in Healthcare Cost

Intervention	Intervention cost, Median (IQI) No. of studies	Change in healthcare cost, Median (IQI) No. of studies	Median time horizon, months	No. of modeled studies	Studies with comparison to other than usual care
SMBP alone	\$60 (\$55 to \$74) ^a 7 ^{21-24,27-31}	-\$148 (-\$316 to -\$89) 8 ^{21-27,29-31}	12	2 ^{21,25,26}	Clinic plus ambulatory BP ²³
SMBP with additional support	\$174 (\$63 to \$362) ^a 7 ^{32-36,38,39}	-\$3 (-\$58 to \$62) 6 ^{33,35-39}	9	2 ^{35,39}	None
SMBP within team-based care	\$732 (\$279 to \$946) ^b 6 ^{22,27,33,40-42,44,45,49}	\$369 (\$57 to \$548) 5 ^{22,27,33,41,42,44,46-49}	18	None	None

^aPer person.^bPer person per year.

BP, blood pressure; IQI, interquartile interval; SMBP, self-measured blood pressure.

additional support, included costs of outpatient visits and medication when estimating the change in healthcare cost. Most studies of SMBP within TBC included outpatient visits, medication, and inpatient stays. The median change in healthcare cost from SMBP alone was a decrease of \$148 per person per year (Table 1). All but one^{22,27} of the eight estimates^{21-27,29-31} showed decreases, indicating SMBP alone was healthcare cost saving, with some of the savings likely from identification of “white coat hypertension.” The median change in healthcare cost from SMBP with additional support was a reduction of \$3 per person per year, based on six estimates^{33,35-39}; individual estimates were mixed, with three estimates^{36,37,39} indicating healthcare cost decreased and three indicating healthcare cost increased or was unchanged. For SMBP within TBC, seven^{22,27,33,41,46-48} of eight estimates^{22,27,33,41,42,44,46-49} reported a positive change in healthcare cost, indicating the intervention was healthcare cost increasing with a median increase of \$369 per person per year.

The summary of estimates for intervention cost plus change in healthcare cost attributable to intervention (total cost) is presented in Table 2. Details for individual studies are in Appendix Table 5 (available online). For SMBP-alone interventions, the median total cost was -\$72. Five^{21,23,24,29-31} of six estimates^{21-24,27,29-31} were negative, indicating the intervention was cost saving, with savings likely to include the use of home BP monitors as a diagnostic tool. The median total cost for SMBP with additional support was \$44, with five^{33,35,36,38,39} of six estimates^{33,35-39} being positive, indicating the intervention increased costs. In the case of SMBP within TBC interventions, median total cost was \$430, with all seven estimates^{22,27,33,41-44,49} positive and, therefore, cost increasing.

Table 2 also summarizes the 20-year cost per QALY saved (based on two methods^{14,15} described previously for translating reductions in SBP to QALYs saved).

Details for individual studies are shown in Appendix Table 6 (available online). Two studies^{23,29} of SMBP alone showed that SBP decreased following intervention and that averted healthcare cost exceeded intervention cost, whereas three studies^{22,24,27,30,31} indicated SMBP alone was not cost effective. Of these three studies, SBP was higher at the end of the intervention in two studies,^{24,30,31} and the third study^{22,27} had a cost per QALY saved >\$50,000. For SMBP with additional support, the median costs per QALY saved, based on the two translation methods, were \$2,800 and \$4,000, with every individual estimate^{33,35,36,38} <\$50,000, indicating cost effectiveness. Median cost per QALY saved for SMBP within TBC was \$7,500 and \$10,800, respectively, for the two translation methods, based on six estimates from four^{22,27,33,41,42,44,49} studies. Of the six estimates, four estimates from the four studies^{22,27,33,41,42,44,49} were <\$50,000 and two estimates from one study^{42,44,49} were >\$50,000; the weight of evidence indicates cost effectiveness.

DISCUSSION

The review of effectiveness found that SMBP monitoring interventions improved BP outcomes based on studies that used the devices as a tool to manage the treatment of high BP.^{5,6,50} This economic review included economic outcomes from the use of home BP devices as a diagnostic tool in addition to their use in guiding treatment. This diagnostic feature was prominent only in the SMBP-alone studies.

The U.S. Preventive Services Task Force recommends confirmation of high BP before beginning treatment, with measurements taken outside the clinic setting using ambulatory or home BP monitoring.⁵¹ Self-measured blood pressure devices could, in practice, be distributed to primary care patients identified with elevated BP by

Table 2. Summary Economic Estimates: Total Cost and 20-Year Total Cost per QALY Saved

Intervention	Total cost (intervention cost plus healthcare cost), Median (IQI) No. of studies	Median time horizon, months	No. of modeled studies	Studies with comparison to other than usual care	Total cost per QALY saved; summed over 20 years, Mean or Median (IQI) No. of studies
SMBP alone	-\$72 (-\$257 to \$142) ^a 6 ^{21-24,27,29-31}	12	1 ²¹	Clinic plus ambulatory BP ²³	Translation (1): ^b Mean \$100,000 Translation (2): Mean \$144,000 1 ^{22,27} Cost-saving 2 ^{23,29} Ineffective (SBP increased) 2 ^{24,30,31}
SMBP with additional support	\$44 (\$6 to \$250) ^a 6 ^{33,35-39}	9	2 ^{35,39}	None	Translation (1): ^b \$2,800 (\$525 to \$5,100) Translation (2): \$4,000 (\$756 to \$7,400) 4 ^{33,35,36,38}
SMBP within team-based care	\$430 (\$244 to \$1,112) ^c 5 ^{22,27,33,41-44,49}	18	None	Usual care with home BP device ⁴³	Translation (1): ^b \$7,500 (\$4,600 to \$79,100) Translation (2): \$10,800 (\$6,600 to \$113,900) 4 ^{22,27,33,41,42,44,49}

^aPer person.

^bTranslation (1): -1 mmHg of SBP=0.009 QALY saved per year¹⁴; Translation (2): -1 mmHg of SBP=0.093 QALY saved over patient's lifetime.¹⁵

^cPer person per year.

BP, blood pressure; IQI, interquartile interval; QALY, quality-adjusted life year; SBP, systolic blood pressure; SMBP, self-measured blood pressure

clinic readings and not yet confirmed with ambulatory BP monitoring. In this scenario, the ability of these devices to identify patients with white coat and masked hypertension would have important implications for the economics of SMBP interventions, potentially reducing treatment cost for white coat and increasing treatment cost for masked hypertension. The diagnostic and treatment features of the devices were captured in the subgroup analysis by Arietta et al.,²¹ who modeled an SMBP intervention for adult members of a health plan. The savings from the diagnostic and treatment features of SMBP were reflected in a favorable return on investment for young adults, driven by savings from correct diagnosis of hypertension, and favorable return on investment for Medicare members, driven by treatment benefits.

Limitations

A relatively large body of evidence for SMBP alone showed that averted healthcare cost exceeded the cost to implement these interventions. However, healthcare cost in most of the studies did not include inpatient stays or ER visits, and the change in healthcare cost was measured over a relatively short period of about 12 months and also included the use of BP devices as a diagnostic tool. Longer-term outcomes from using SMBP for hypertension treatment, which account for all components of healthcare, are necessary to determine benefits from improved BP control and averted CVD outcomes. Further, two studies^{24,30,31} reported increased SBP

following the intervention. The unfavorable BP outcomes have been ascribed to identical BP thresholds chosen for both intervention and usual care groups instead of a lower threshold for home measurements, as currently recommended.⁵² The change in healthcare cost also included savings from identifying patients with white coat hypertension and taking some patients off medication, even as benefits of treating white coat hypertension are still debated.⁵³ These cost savings were therefore not highlighted for SMBP-alone interventions.

The translation of reduced SBP to QALYs saved was based on two published formulae that are in turn drawn from large longitudinal trials within diabetic populations. Even though it is possible that the overall QALYs may be lower for diabetic patients than hypertensive patients, the relative impact of SBP reduction on the QALYs of diabetic patients compared with that of hypertensive patients is uncertain. [Appendix Table 1](#) (available online) also includes the percentage of the study population that were identified as diabetic, where reported. It may be noted that three included studies explicitly excluded diabetic patients, and 11 did not report any information. For the remaining seven studies, the median and mean percentages of diabetics included in their interventions were 24% and 30%, respectively.

The direct translation of reduced SBP to QALYs saved used in the present review may yet be an oversimplification of the complex processes by which reduced SBP averts CVD outcomes. A related issue is whether there is

a lower limit for SBP below which reductions do not produce health benefits⁵⁴ nor save QALYs. Current guidelines⁵⁵ stipulate a target SBP <140 mmHg for the general hypertensive population, with no consensus about the net benefits of more aggressive treatment to reach a lower target. However, it is likely patients with BP at 160/100 will derive benefit from treatment in moving their BP to 130/80, but might not obtain additional benefit in moving BP to 120/60.⁵⁶ Of nine studies where reduction in SBP was translated to QALYs saved, the mean SBP after the effect of intervention was >140 in five studies,^{23,33,35,36,38} 135–140 in two studies,^{29,41} 120–125 in two studies,^{22,27,42,44,49} and <120 in no studies. Based on these means, it is likely that reductions achieved in SBP from the interventions in this review fell within the beneficial range and increased QALYs.

The Community Preventive Services Task Force recommended TBC based on its effectiveness in improving BP control,⁵⁷ and it also was found to be cost effective.¹³ Studies of SMBP within TBC included in the present review do not provide evidence for the contribution of SMBP to the effectiveness or cost effectiveness of TBC because the studies compared SMBP within TBC to usual care. However, SMBP is a common component of TBC for BP control, as it provides a regular and ongoing activity to engage patients in their own care. SMBP also allows the team of providers to monitor patient response to treatment.

No studies in the present review performed a complete cost–benefit analysis that included improvements in productivity. However, this was partly compensated by cost per QALY estimates computed by the team from translations of reductions in SBP to QALYs saved.

Evidence Gaps

Studies that use SMBP monitoring as a diagnostic tool in addition to treatment should try to separate out their contributing effects on economic outcomes. Although it may be difficult to do this analytically, the diagnostic effect may be approximated, for example, in terms of discontinued or newly initiated treatments. More studies are needed for estimating return on investment for SMBP-alone interventions, capturing longer-term changes in healthcare cost because of changes in morbidity and mortality. There is stronger evidence and greater effectiveness when patient support or TBC is added to SMBP monitoring, but there is no cost-effectiveness evidence for adding various levels of such support, indicating another item for future research.

CONCLUSIONS

When used with additional patient support or within TBC, SMBP monitoring interventions are cost effective.

Though short-term healthcare costs averted were greater than cost of intervention, the evidence for cost effectiveness of SMBP interventions when used alone was mixed and inconsistent.

The findings of this economic review, together with the conclusions of the review on effectiveness,⁷ support the recommendations for use of SMBP interventions presented by the Community Preventive Services Task Force elsewhere in this issue.⁵⁰ These results and findings can contribute to the evidence for SMBP for improved BP management and control as clinical guidelines for the prevention and treatment of hypertension are updated.

ACKNOWLEDGMENTS

The authors acknowledge the Division for Heart Disease and Stroke Prevention, Center for Disease Control and Prevention (CDC), for support and subject matter expertise. We thank members of our coordination team in the Community Guide Branch at CDC and from other areas of CDC, and our external partners. The authors also thank Randy W. Elder, PhD, and Kate W. Harris, BA, from the Community Guide Branch, and Onnalee Gomez, MS, from the Library Services Branch, at CDC for their assistance throughout the review.

The work of Jeffrey Reynolds was supported with funds from the Oak Ridge Institute for Science and Education.

No financial disclosures were reported by the authors of this paper.

SUPPLEMENTAL MATERIAL

Supplemental materials associated with this article can be found in the online version at <https://www.thecommunityguide.org/sites/default/files/assets/cvd-ajpm-app-smbp.pdf>.

REFERENCES

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics—2016 Update. A report from the American Heart Association. *Circulation*. 2016;133(4):447–454. <https://doi.org/10.1161/CIR.0000000000000366>.
2. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63(25, pt B):2935–2959. <https://doi.org/10.1016/j.jacc.2013.11.005>.
3. Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States. A policy statement from the American Heart Association and American Stroke Association. *Stroke*. 2013;44(8):2361–2375. <https://doi.org/10.1161/STR.0b013e31829734f2>.
4. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. *Stroke*. 2014;45(1):315–353. <https://doi.org/10.1161/01.str.0000437068.30550.cf>.
5. Uhlig K, Balk EM, Patel K, et al. Self-measured blood pressure monitoring: comparative effectiveness [Internet]. *Comparative Effectiveness Reviews No. 45*. Rockville, MD: Agency for Healthcare Research and Quality; 2012. www.ncbi.nlm.nih.gov/pubmed/22439158. Accessed August 30, 2016.

6. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. *Ann Intern Med.* 2013;159(3):185–194. <https://doi.org/10.7326/0003-4819-159-3-201308060-00008>.
7. Community Preventive Services Task Force. Cardiovascular disease prevention: self-measured blood pressure monitoring interventions for improved blood pressure control. www.thecommunityguide.org/sites/default/files/assets/CVD-Self-Measured-Blood-Pressure_2.pdf. Published 2015. Accessed August 30, 2016.
8. Fagard R. White-coat and masked hypertension. In: Mancia G, Grassi G, Redon J, eds. *Manual of Hypertension of the European Society of Hypertension, Second Edition*. Boca Raton, FL: CRC Press; 2014:443–448. <https://doi.org/10.1201/b17072-47>.
9. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. *BMJ.* 2011;342:d3621. <https://doi.org/10.1136/bmj.d3621>.
10. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. *Lancet.* 2011;378(9798):1219–1230. [https://doi.org/10.1016/S0140-6736\(11\)61184-7](https://doi.org/10.1016/S0140-6736(11)61184-7).
11. Eichler H-G, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? *Value Health.* 2004;7(5):518–528. <https://doi.org/10.1111/j.1524-4733.2004.75003.x>.
12. Grosse SD. Assessing cost-effectiveness in healthcare: history of the \$50,000 per QALY threshold. *Expert Rev Pharmacoecon Outcomes Res.* 2008;8(2):165–178. <https://doi.org/10.1586/14737167.8.2.165>.
13. Jacob V, Chattopadhyay SK, Thota AB, et al. Economics of team-based care in controlling blood pressure: a Community Guide systematic review. *Am J Prev Med.* 2015;49(5):772–783. <https://doi.org/10.1016/j.amepre.2015.04.003>.
14. McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). *Curr Med Res Opin.* 2006;22(1):121–129. <https://doi.org/10.1185/030079906X80350>.
15. Mason JM, Freemantle N, Gibson JM, New JP. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. *Diabetes Care.* 2005;28(1):40–46. <https://doi.org/10.2337/diacare.28.1.40>.
16. Bureau of Labor Statistics. CPI Detailed Report: Data for December 2015. www.bls.gov/cpi/cpid1512.pdf. Published 2010.
17. World Bank. Purchasing power parities. September 6, 2016. data. worldbank.org/indicator/PA.NUS.PRVT.PP.
18. World Bank Country and Lending Groups. <http://data.worldbank.org/about/country-and-lending-groups>. Published 2010. Accessed August 30, 2016.
19. CDC. Self-measured blood pressure monitoring: action steps for public health practitioners. millionhearts.hhs.gov/files/MH_SMBP.pdf. Published 2013. Accessed August 30, 2016.
20. CDC. Self-measured blood pressure monitoring: actions steps for clinicians. millionhearts.hhs.gov/files/MH_SMBP_Clinicians.pdf. Published 2014. Accessed August 30, 2016.
21. Arrieta A, Woods JR, Qiao N, Jay SJ. Cost-benefit analysis of home blood pressure monitoring in hypertension diagnosis and treatment: an insurer perspective. *Hypertension.* 2014;64(4):891–896. <https://doi.org/10.1161/HYPERTENSIONAHA.114.03780>.
22. Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control: a randomized trial. *Ann Intern Med.* 2009;151(10):687–695. <https://doi.org/10.7326/0000605-200911170-00148>.
23. Boubouchairopoulou N, Karpettas N, Athanasakis K, et al. Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements. *J Am Soc Hypertens.* 2014;8(10):732–738. <https://doi.org/10.1016/j.jash.2014.07.027>.
24. Den Hond E, Staessen JA, Celis H, et al. Antihypertensive treatment based on home or office blood pressure—the THOP trial. *Blood Press Monit.* 2004;9(6):311–314. <https://doi.org/10.1097/00126097-200412000-00008>.
25. Fukunaga H, Ohkubo T, Kobayashi M, et al. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. *J Hypertens.* 2008;26(4):685–690. <https://doi.org/10.1097/HJH.0b013e3282f42285>.
26. Funahashi J, Ohkubo T, Fukunaga H, et al. The economic impact of the introduction of home blood pressure measurement for the diagnosis and treatment of hypertension. *Blood Press Monit.* 2006;11(5):257–267. <https://doi.org/10.1097/01.mbp.0000217996.19839.70>.
27. Reed SD, Li Y, Oddone EZ, et al. Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension. *Am J Hypertens.* 2010;23(2):142–148. <https://doi.org/10.1038/ajh.2009.215>.
28. Rogers MA, Small D, Buchan DA, et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension: a randomized, controlled trial. *Ann Intern Med.* 2001;134(11):1024–1032. <https://doi.org/10.7326/0003-4819-134-11-200106050-00008>.
29. Soghikyan K, Casper SM, Fireman BH, et al. Home blood pressure monitoring. Effect on use of medical services and medical care costs. *Med Care.* 1992;30(9):855–865. <https://doi.org/10.1097/00005650-199209000-00009>.
30. Staessen JA, Den Hond E, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. *JAMA.* 2004;291(8):955–964. <https://doi.org/10.1001/jama.291.8.955>.
31. Verberk WJ, Kroon AA, Lenders JWM, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. *Hypertension.* 2007;50(6):1019–1025. <https://doi.org/10.1161/HYPERTENSIONAHA.107.094193>.
32. Bondmass M, Bolger N, Castro G, Avital B. The effect of home monitoring and telemanagement on blood pressure control among African Americans. *Telemed J.* 2000;6(1):15–23. <https://doi.org/10.1089/107830200311815>.
33. Fishman PA, Cook AJ, Anderson ML, et al. Improving BP control through electronic communications: an economic evaluation. *Am J Manag Care.* 2013;19(9):709–716.
34. Friedman RH, Kazis LE, Jette A, et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. *Am J Hypertens.* 1996;9(4, pt 1):285–292. [https://doi.org/10.1016/0895-7061\(95\)00353-3](https://doi.org/10.1016/0895-7061(95)00353-3).
35. Kaambwa B, Bryan S, Jowett S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis. *Eur J Prev Cardiol.* 2014;21(12):1517–1530. <https://doi.org/10.1177/2047487313501886>.
36. Madsen LB, Christiansen T, Kirkegaard P, Pedersen EB. Economic evaluation of home blood pressure telemonitoring: a randomized controlled trial. *Blood Press.* 2011;20(2):117–125. <https://doi.org/10.3109/08037051.2010.532306>.
37. Parati G, Omboni S, Albini F, et al. Home blood pressure telemonitoring improves hypertension control in general practice: the TeleBPCare study. *J Hypertens.* 2009;27(1):198–203. <https://doi.org/10.1097/HJH.0b013e3283163caf>.
38. Stoddart A, Hanley J, Wild S, et al. Telemonitoring-based service redesign for the management of uncontrolled hypertension (HITS): cost and cost-effectiveness analysis of a randomised controlled trial. *BMJ Open.* 2013;3(5):e002681. <https://doi.org/10.1136/bmjopen-2013-002681>.
39. Trogon JG, Larsen B, Larsen D, Salas W, Snell M. Cost-effectiveness evaluation of a collaborative patient education hypertension intervention in Utah. *J Clin Hypertens (Greenwich).* 2012;14(11):760–766. <https://doi.org/10.1111/jch.12013>.

40. Artinian NT, Washington OG, Templin TN. Effects of home telemonitoring and community-based monitoring on blood pressure control in urban African Americans: a pilot study. *Heart Lung*. 2001;30(3):191–199. <https://doi.org/10.1067/mhl.2001.112684>.
41. Billups SJ, Moore LR, Olson KL, Magid DJ. Cost-effectiveness evaluation of a home blood pressure monitoring program. *Am J Manag Care*. 2014;20(9):e380–e387.
42. Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. *Arch Intern Med*. 2011;171(13):1173–1180. <https://doi.org/10.1001/archinternmed.2011.276>.
43. Johannesson M, Aberg H, Agreus L, Borgquist L, Jonsson B. Cost-benefit analysis of non-pharmacological treatment of hypertension. *J Intern Med*. 1991;230(4):307–312. <https://doi.org/10.1111/j.1365-2796.1991.tb00449.x>.
44. Maciejewski ML, Bosworth HB, Olsen MK, et al. Do the benefits of participation in a hypertension self-management trial persist after patients resume usual care? *Circ Cardiovasc Qual Outcomes*. 2014;7(2):269–275. <https://doi.org/10.1161/CIRCOUTCOMES.113.000309>.
45. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. *JAMA*. 2013;310(1):46–56. <https://doi.org/10.1001/jama.2013.6549>.
46. Palmas W, Shea S, Starren J, et al. Medicare payments, healthcare service use, and telemedicine implementation costs in a randomized trial comparing telemedicine case management with usual care in medically underserved participants with diabetes mellitus (IDEATel). *J Am Med Inform Assoc*. 2010;17(2):196–202. <https://doi.org/10.1136/jamia.2009.002592>.
47. Shea S, Weinstock RS, Starren J, et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus. *J Am Med Inform Assoc*. 2006;13(1):40–51. <https://doi.org/10.1197/jamia.M1917>.
48. Shea S, Weinstock RS, Teresi JA, et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. *J Am Med Inform Assoc*. 2009;16(4):446–456. <https://doi.org/10.1197/jamia.M3157>.
49. Wang V, Smith VA, Bosworth HB, et al. Economic evaluation of telephone self-management interventions for blood pressure control. *Am Heart J*. 2012;163(6):980–986. <https://doi.org/10.1016/j.ahj.2012.03.016>.
50. Community Preventive Services Task Force. Self-measured blood pressure monitoring improves outcomes: recommendation of the Community Preventive Services Task Force. *Am J Prev Med*. 2017;53(3):e115–e118.
51. Siu AL. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2015;163(10):778–786. <https://doi.org/10.7326/M15-2223>.
52. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. *J Hypertens*. 2008;26(8):1505–1526. <https://doi.org/10.1097/HJH.0b013e328308da66>.
53. Weber MA, Turner JR. Ambulatory blood pressure monitoring: new directions and uncertainties arise from the U.S. Preventive Services Task Force recommendation on the diagnosis of hypertension. *J Clin Hypertens*. 2016;18(3):172–174. <https://doi.org/10.1111/jch.12798>.
54. Banach M, Aronow WS. Blood pressure J-curve: current concepts. *Curr Hypertens Rep*. 2012;14(6):556–566. <https://doi.org/10.1007/s11906-012-0314-3>.
55. NIH, National Heart Lung and Blood Institute. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). www.nhlbi.nih.gov/health-pro/guidelines/current/hypertension-jnc-7. Accessed August 31, 2016.
56. Valdiviezo C, Martin LW, Panjath GS. The lower the achieved blood pressure goal the better. *Curr Opin Cardiol*. 2015;30(4):378–382. <https://doi.org/10.1097/hco.0000000000000187>.
57. Community Preventive Services Task Force. Team-based care to improve blood pressure control: recommendation of the Community Preventive Services Task Force. *Am J Prev Med*. 2014;47(1):100–102. <https://doi.org/10.1016/j.amepre.2014.03.003>.